Literature DB >> 20425056

Mechanisms of HIV latency: an emerging picture of complexity.

David M Margolis1.   

Abstract

Rarely HIV type 1 establishes proviral latency within the host genome, maintained with little or no viral gene expression. This state has been quantitated in peripheral blood and lymphoid tissues of HIV-infected patients, appearing in the earliest days of infection. These rare cellular reservoirs are unaffected by current antiretroviral therapy and unrecognized by the host immune response, and can regenerate disseminated viremia if therapy is interrupted. Proviral latency may be established when a newly HIV-infected cell exits the cell cycle and returns to the resting state. Rarely, direct infection of resting cells may also occur. Multiple molecular mechanisms appear to underlie the establishment and maintenance of persistent, latent HIV infection, most frequent in the resting central memory CD4+ T cell. Interrupting processes that maintain latency may allow therapeutic attack of this primary form of persistent HIV infection, but a better understanding of relevant mechanisms in vivo is needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425056     DOI: 10.1007/s11904-009-0033-9

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  43 in total

1.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

2.  Attacking latent HIV provirus: from mechanism to therapeutic strategies.

Authors:  Nancy M Archin; David M Margolis
Journal:  Curr Opin HIV AIDS       Date:  2006-03       Impact factor: 4.283

3.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

4.  Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.

Authors:  C Fraser; N M Ferguson; A C Ghani; J M Prins; J M Lange; J Goudsmit; R M Anderson; F de Wolf
Journal:  AIDS       Date:  2000-04-14       Impact factor: 4.177

5.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

6.  The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.

Authors:  J J Coull; F Romerio; J M Sun; J L Volker; K M Galvin; J R Davie; Y Shi; U Hansen; D M Margolis
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

7.  The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation.

Authors:  A Jordan; P Defechereux; E Verdin
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

8.  Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough.

Authors:  Yefei Han; Yijie B Lin; Wenfeng An; Jie Xu; Hung-Chih Yang; Karen O'Connell; Dominic Dordai; Jef D Boeke; Janet D Siliciano; Robert F Siliciano
Journal:  Cell Host Microbe       Date:  2008-08-14       Impact factor: 21.023

9.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

10.  Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.

Authors:  E Verdin; P Paras; C Van Lint
Journal:  EMBO J       Date:  1993-08       Impact factor: 11.598

View more
  45 in total

Review 1.  Transcriptional and posttranscriptional regulation of HIV-1 gene expression.

Authors:  Jonathan Karn; C Martin Stoltzfus
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

Review 2.  HIV reservoirs and latency models.

Authors:  Matthew J Pace; Luis Agosto; Erin H Graf; Una O'Doherty
Journal:  Virology       Date:  2011-02-01       Impact factor: 3.616

3.  Scaffold attachment factor B suppresses HIV-1 infection of CD4+ T cells by preventing binding of RNA polymerase II to HIV-1's long terminal repeat.

Authors:  Li Ma; Li Sun; Xia Jin; Si-Dong Xiong; Jian-Hua Wang
Journal:  J Biol Chem       Date:  2018-06-10       Impact factor: 5.157

4.  Treatment of chronically FIV-infected cats with suberoylanilide hydroxamic acid.

Authors:  Samantha J McDonnel; Molly L Liepnieks; Brian G Murphy
Journal:  Antiviral Res       Date:  2014-06-02       Impact factor: 5.970

5.  Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2.

Authors:  Julia Friedman; Won-Kyung Cho; Chung K Chu; Kara S Keedy; Nancie M Archin; David M Margolis; Jonathan Karn
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

Review 6.  Interaction between endogenous bacterial flora and latent HIV infection.

Authors:  Ann Florence B Victoriano; Kenichi Imai; Takashi Okamoto
Journal:  Clin Vaccine Immunol       Date:  2013-04-24

7.  Modeling the timing of antilatency drug administration during HIV treatment.

Authors:  Janka Petravic; Alexey Martyushev; Jeanette C Reece; Stephen J Kent; Miles P Davenport
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

8.  HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

Authors:  Nancy M Archin; Rosalie Bateson; Manoj K Tripathy; Amanda M Crooks; Kuo-Hsiung Yang; Noelle P Dahl; Mary F Kearney; Elizabeth M Anderson; John M Coffin; Matthew C Strain; Douglas D Richman; Kevin R Robertson; Angela D Kashuba; Ronald J Bosch; Daria J Hazuda; Joann D Kuruc; Joseph J Eron; David M Margolis
Journal:  J Infect Dis       Date:  2014-03-11       Impact factor: 5.226

9.  A CRISPR Approach for Reactivating Latent HIV-1.

Authors:  Angel Lin; Zachary Klase
Journal:  Mol Ther       Date:  2016-03       Impact factor: 11.454

10.  TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy.

Authors:  So-Yon Lim; Christa E Osuna; Peter T Hraber; Joe Hesselgesser; Jeffrey M Gerold; Tiffany L Barnes; Srisowmya Sanisetty; Michael S Seaman; Mark G Lewis; Romas Geleziunas; Michael D Miller; Tomas Cihlar; William A Lee; Alison L Hill; James B Whitney
Journal:  Sci Transl Med       Date:  2018-05-02       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.